VANCOUVER, BC — September 18, 2025 — Leads & Copy — USA News Group News Commentary –Avant Technologies, Inc. (OTCQB: AVAI) has entered the longevity biotechnology sector through a joint venture with Austrianova, establishing Klothonova, Inc. focused on cell-based therapies. This positions Avant at the forefront of anti-aging therapeutics, leveraging Austrianova’s cell-encapsulation technology.
The joint venture targets Alzheimer’s, heart disease, cancer, kidney disease, and other age-related conditions. Austrianova brings intellectual property backed by over 50 peer-reviewed publications and partnerships, while Avant provides capital to accelerate Klothonova’s development pipeline.
Chris Winter, CEO at Avant Technologies, stated the partnership complements their vision for advancing transformative healthcare solutions. Brian Salmons, CEO at Austrianova, added the partnership allows them to combine proprietary technologies with Avant’s resources to accelerate the development of Klotho-based therapies.
HCW Biologics Inc. (NASDAQ: HCWB) has designated HCW11-040 as its franchise immunotherapeutic for internal clinical development targeting solid tumors. Preclinical data showed HCW11-040 outperformed pembrolizumab monotherapy in immune-cell activation, tumor infiltration enhancement, and cytotoxicity against cancer cells.
Solid Biosciences Inc. (NASDAQ: SLDB) has dosed 15 participants in its Phase 1/2 INSPIRE DUCHENNE trial for SGT-003 gene therapy targeting Duchenne muscular dystrophy. The company ended Q2 2025 with $268.1 million in cash, cash equivalents, and available-for-sale securities, providing runway into the first half of 2027.
ProMIS Neurosciences Inc. (NASDAQ: PMN) received DSMB approval to advance to the final dose escalation cohort in its Phase 1b PRECISE-AD trial of PMN310 for Alzheimer’s disease treatment. The independent Data and Safety Monitoring Board’s unanimous recommendation followed review of safety data through Cohort 2, which has been fully enrolled.
uniQure N.V. (NASDAQ: QURE) achieved sustained increases in α-Gal A enzyme activity ranging from 27- to 208-fold above mean normal levels in all four patients from the first cohort of its Phase I/IIa trial of AMT-191 gene therapy for Fabry disease.
Contact:USA NEWS GROUPinfo@usanewsgroup.com(604) 265-2873
Source: USA News Group
